Scholarlink

<p>Resistant hypertension remains a major clinical challenge despite multidrug therapy. Baxdrostat, a highly selective aldosterone synthase inhibitor, has emerged as a novel treatment option. We conducted an updated systematic review and meta-analysis to evaluate its efficacy and safety. PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov were searched through April 30, 2026, for randomized controlled trials comparing baxdrostat with control in uncontrolled or resistant hypertension. Random-effects meta-analyses, Trial Sequential Analysis (TSA), subgroup/sensitivity analyses, risk of bias, and GRADE evaluations were performed. Baxdrostat significantly reduced seated systolic blood pressure (SBP) overall (MD: − 6.69&#xa0;mmHg, 95% CI: − 9.30 to − 4.07; <i>p</i> &lt; 0.00001) and in the resistant hypertension subgroup. Significant reductions were also observed in seated diastolic, 24-h ambulatory, and night-time ambulatory SBP (all <i>p</i> &lt; 0.001), leading to higher achievement of target BP &lt; 130&#xa0;mmHg. Mechanistically, baxdrostat significantly increased hyperkalemia risk (RR: 3.84, 95% CI: 1.82 to 8.11) and serum potassium elevations &gt; 5.5 and &gt; 6.0&#xa0;mmol/L. Crucially, severe hyperkalemia (6.5&#xa0;mmol/L) did not increase significantly. While overall adverse events were more frequent, serious adverse events, hypotension, hyponatremia, mortality, and discontinuation due to hyperkalemia were comparable between groups. TSA confirmed conclusive evidence for SBP reduction. Baxdrostat, particularly at 2&#xa0;mg, provides clinically meaningful BP reductions. Anticipated potassium elevations (&gt; 5.5 and &gt; 6.0&#xa0;mmol/L) serve as a safety signal requiring cautious monitoring, but the absence of significant severe hyperkalemia (&gt; 6.5&#xa0;mmol/L) highlights a reassuring safety profile. Serious safety outcomes remain entirely comparable to control.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Can baxdrostat redefine blood pressure control in resistant and uncontrolled hypertension? a systematic review, meta-analysis, and trial sequential analysis

  • 期刊论文

  • 发表日期：

    2026年7月29日

查看全文
  • Bilal Wazir Khan,
  • Muhammad Yahya,
  • Hamza Wazir Khan,
  • Miguel Alejandro Rivas Perez,
  • Tayyaba Ikram Qazi,
  • Humaira Obaid,
  • Muhammad Mustafa Khan,
  • Muhammad Maaz Amjad,
  • Muhammad Faaz Khan,
  • Aneeq Mahmood Khan,
  • Muhammad Junaid Khan,
  • Sajjad Khan,
  • Aleena Amir Malik,
  • Fatima Haneef,
  • Muhammad Huzaifa Khattak,
  • Atta Ur Rahman,
  • Shaheer Ullah Khan,
  • Saeeda Zahid

摘要

Resistant hypertension remains a major clinical challenge despite multidrug therapy. Baxdrostat, a highly selective aldosterone synthase inhibitor, has emerged as a novel treatment option. We conducted an updated systematic review and meta-analysis to evaluate its efficacy and safety. PubMed, Embase, Scopus, Cochrane Library, and ClinicalTrials.gov were searched through April 30, 2026, for randomized controlled trials comparing baxdrostat with control in uncontrolled or resistant hypertension. Random-effects meta-analyses, Trial Sequential Analysis (TSA), subgroup/sensitivity analyses, risk of bias, and GRADE evaluations were performed. Baxdrostat significantly reduced seated systolic blood pressure (SBP) overall (MD: − 6.69 mmHg, 95% CI: − 9.30 to − 4.07; p < 0.00001) and in the resistant hypertension subgroup. Significant reductions were also observed in seated diastolic, 24-h ambulatory, and night-time ambulatory SBP (all p < 0.001), leading to higher achievement of target BP < 130 mmHg. Mechanistically, baxdrostat significantly increased hyperkalemia risk (RR: 3.84, 95% CI: 1.82 to 8.11) and serum potassium elevations > 5.5 and > 6.0 mmol/L. Crucially, severe hyperkalemia (6.5 mmol/L) did not increase significantly. While overall adverse events were more frequent, serious adverse events, hypotension, hyponatremia, mortality, and discontinuation due to hyperkalemia were comparable between groups. TSA confirmed conclusive evidence for SBP reduction. Baxdrostat, particularly at 2 mg, provides clinically meaningful BP reductions. Anticipated potassium elevations (> 5.5 and > 6.0 mmol/L) serve as a safety signal requiring cautious monitoring, but the absence of significant severe hyperkalemia (> 6.5 mmol/L) highlights a reassuring safety profile. Serious safety outcomes remain entirely comparable to control.